Medical Innovation Prize Act of 2005

Bill: 109-hr-417
Sponsor: Rep. Sanders, Bernard [I-VT-At Large]
Introduced: 2005-01-26 in the House
Policy area: Health
Subjects: AIDS (Disease)
Advice and consent of the Senate
Antibiotics
Armed Forces and National Security
Awards, medals, prizes
Biological warfare
Citizen participation
Commemorations
Commerce
Commercial arbitration
Communicable diseases
Compensation (Law)
Congress
Congressional investigations
Congressional reporting requirements
Crime and Law Enforcement
Developing countries
Drug approvals
Drug industry
Drugs
Economics and Public Finance
Executive reorganization
Federal advisory bodies
Government Operations and Politics
Intellectual property
International Affairs
Law
Medical innovations
Orphan drugs
Patents
Pharmaceutical research
Presidential appointments
Research and development
Revolving funds
Science, Technology, Communications
Terrorism
Trusts and trustees
Vaccines
Valuation
World health

Summary:
action_date: 2005-01-26
text: 
Medical Innovation Prize Act of 2005 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use a drug, a biological product, or a manufacturing process for a drug or biological product in interstate commerce, notwithstanding current Federal laws providing otherwise, including laws governing patent rights or exclusive marketing periods. 
 
Establishes the Fund for Medical Innovation Prizes. Requires the Board of Trustees for the Fund to award prize payments for medical innovations relating to a drug, biological product, or manufacturing process for a drug or biological product. Requires an eligible award recipient to be either the first person to receive market clearance or the holder of the patent. Directs the Board to consider: (1) the number of patients who benefited from the drug, including non-U.S. patients; (2) the incremental therapeutic benefit of the drug to treat the same disease or condition; (3) the degree to which the drug addresses priority health care needs, such as global infectious diseases and neglected diseases that primarily afflict the poor in developing countries; and (4) the improved efficiency of manufacturing processes for drugs or biological processes. Allows the Board to award prize payments for no more than ten years. Allocates certain minimum payments from the Fund for priority research and development.
 
Requires the Comptroller General to conduct an audit to determine the Board's effectiveness in bringing to market new drugs, vaccines, biological products, and manufacturing processes in a cost-effective manner and addressing society's global medical needs.


Legislative actions:
action_date: 2005-03-02
text: Referred to the Subcommittee on Courts, the Internet, and Intellectual Property.
action_date: 2005-02-25
text: Referred to the Subcommittee on Health.
action_date: 2005-02-02
text: Sponsor introductory remarks on measure. (CR E149)
action_date: 2005-01-26
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2005-01-26
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2005-01-26
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2005-01-26
text: Sponsor introductory remarks on measure. (CR E130-131)
action_date: 2005-01-26
text: Introduced in House
action_date: 2005-01-26
text: Introduced in House